Abcam Plc (LON:ABC) had its price target increased by analysts at JPMorgan Chase & Co. from GBX 678 ($8.52) to GBX 864 ($10.86) in a note issued to investors on Monday. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.’s price target indicates a potential upside of 4.66% from the stock’s previous close.
Several other brokerages also recently commented on ABC. Numis Securities Ltd downgraded Abcam Plc to a “hold” rating and set a GBX 912 ($11.46) price objective on the stock. in a research report on Tuesday, March 7th. Peel Hunt restated a “hold” rating and issued a GBX 750 ($9.43) price objective on shares of Abcam Plc in a research report on Monday, March 6th. Finally, Panmure Gordon restated a “sell” rating and issued a GBX 680 ($8.55) price objective on shares of Abcam Plc in a research report on Monday, March 20th. One analyst has rated the stock with a sell rating and five have issued a hold rating to the company. Abcam Plc currently has an average rating of “Hold” and an average price target of GBX 763.20 ($9.59).
Shares of Abcam Plc (LON:ABC) remained flat at GBX 825.50 during midday trading on Monday. 477,772 shares of the stock were exchanged. The company’s market cap is GBX 1.67 billion. The stock’s 50 day moving average price is GBX 861.08 and its 200-day moving average price is GBX 835.16. Abcam Plc has a 1-year low of GBX 587.00 and a 1-year high of GBX 948.00.
The company also recently announced a dividend, which will be paid on Thursday, April 13th. Stockholders of record on Thursday, March 16th will be issued a GBX 2.83 ($0.04) dividend. The ex-dividend date is Thursday, March 16th. This represents a dividend yield of 0.31%.
In other news, insider Alan Thomas Hirzel bought 6,000 shares of Abcam Plc stock in a transaction dated Monday, March 20th. The shares were purchased at an average cost of GBX 839 ($10.54) per share, with a total value of £50,340 ($63,265.05).
About Abcam Plc
Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.